Tune Therapeutics

Tune Therapeutics, founded in 2020, is a U.S.-based developer of epigenetic editing technology. Utilizing the TEMPO technology platform, it can specifically alter the packing and accessibility of DNA within cells to control the expression levels of individual or multiple genes, addressing currently incurable chronic diseases and more. This process is entirely different from gene editing, which involves cutting and breaking the DNA strand and making irreversible changes to its fundamental coding sequence.